AAA
SGP

Affinity Asset Advisors’s SpyGlass Pharma SGP Stock Holding History

Affinity Asset Advisors’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Sell
131,586
-118,414
-47% -$2.57M 0.13% 93
2026
Q1 		$6.48M Buy
+250,000
New +$6.73M 0.33% 61

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Affinity Asset Advisors's SGP Position: Q2 2026 in Review

Affinity Asset Advisors reduced its SpyGlass Pharma (SGP) stake by 47% in Q2 2026, selling an estimated $2.57M and leaving 131,586 shares worth $2.93M. The position accounts for 0.13% of the portfolio, ranked #93.

Affinity Asset Advisors first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.48M in Q1 2026. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Affinity Asset Advisors held 131,586 shares of SpyGlass Pharma worth $2.93M as of Q2 2026.
  • Affinity Asset Advisors sold 118,414 SpyGlass Pharma shares in Q2 2026, an estimated $2.57M.
  • SpyGlass Pharma made up 0.13% of Affinity Asset Advisors's portfolio in Q2 2026, its #93 holding.
  • Affinity Asset Advisors first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • Affinity Asset Advisors's SpyGlass Pharma position peaked at $6.48M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.